Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.
IPO Year: 2022
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2022 | $14.00 | Speculative Buy | The Benchmark Company |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
The Benchmark Company initiated coverage of Mana Capital Acquisition Corp. with a rating of Speculative Buy and set a new price target of $14.00
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
EFFECT - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
424B5 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
DEL AM - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
S-3 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
Fastest customizable press release news feed in the world
Mana Capital Acquisition Corp. ("Mana Capital") (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))), a publicly traded special purpose acquisition company, today announced that its registration statement on Form S-4, relating to the previously announced business combination between Mana Capital and Cardio Diagnostics, Inc. ("Cardio"), a pioneering precision cardiovascular testing company, has been declared effective by the U.S. Securities and Exchange Commission. Mana Capital has mailed the definitive proxy statement/prospectus (the "Proxy Statement") to stockholders of record as of the close of business on September 27, 2022. The Proxy Statement contains a notice and voting instruction form or a proxy ca
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital"), a special purpose acquisition company ("Mana Capital"), announced today that for the purpose of consummating its previously announced business combination with Cardio Diagnostics, Inc. ("Cardio"), the Company has further extended the date by which it is required to complete a business combination for an additional period of one (1) month from September 26, 2022 to October 26, 2022, and that the amount of $216,667 has been deposited into the Company's trust account (the "Trust Account") in connection with the extension. The funds deposited into the Trust Account were provided by Cardio unde
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital") today announced that its Board of Directors has approved a second extension of the period of time available to the Company to consummate its initial business combination by one month from September 26, 2022 to October 26, 2022 (the "Extension"), as permitted under the Company's amended and restated certificate of incorporation. In connection therewith, pursuant to the merger agreement, dated May 27, 2022, among the Company, Mana Merger Sub, Inc., Cardio Diagnostics, Inc. ("Cardio"), and Meeshanthini (Meesha) Dogan, as representative of the shareholders of Cardio, Cardio is expected to depo
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital"), a special purpose acquisition company ("Mana Capital"), announced today that for the purpose of consummating its previously announced business combination with Cardio Diagnostics, Inc. ("Cardio"), the Company has extended the date by which it is required to complete a business combination for an additional period of one (1) month from August 26, 2022 to September 26, 2022, and that the amount of $216,667 has been deposited into the Company's trust account (the "Trust Account") in connection with the extension. The funds deposited into the Trust Account were provided by Cardio under the ter
Mana Capital Acquisition Corp. (NASDAQ:MAAQU, MAAQ, MAAQW, MAAQR))) (the "Company" or "Mana Capital") today announced that its Board of Directors has approved an extension of the period of time available to the Company to consummate its initial business combination by one month from August 26, 2022 to September 26, 2022 (the "Extension"), as permitted under the Company's amended and restated certificate of incorporation. In connection therewith, pursuant to the merger agreement, dated May 27, 2022, among the Company, Mana Merger Sub, Inc., Cardio Diagnostics, Inc. ("Cardio"), and Meeshanthini (Meesha) Dogan, as representative of the shareholders of Cardio, Cardio is expected to deposit $21
Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine™ that enables improved diagnosis and prevention of cardiovascular disease The Company's flagship product, Epi+Gen CHD™, is a highly sensitive and accessible clinical test that assesses the 3-year risk for coronary heart disease, which is the most common type of heart disease and the major cause of heart attacks(1) Cardio Diagnostics' cash on the balance sheet prior to closing is expected to fund the combined company's operations through the end of 2023 The combined company's Chairman will be Warren Hosseinion, MD, current President of Nasdaq-listed Nutex Health, In
This live feed shows all institutional transactions in real time.
SC 13G - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13D - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
SC 13G - Mana Capital Acquisition Corp. (0001870144) (Subject)
SC 13G/A - Mana Capital Acquisition Corp. (0001870144) (Subject)